Publication | Closed Access

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors

MedicinePharmacologyAdvanced Solid TumorsPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyPharmacodynamic Trial